{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-029261","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.462354+00:00","generated_at":"2026-06-21T03:13:08.356818+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Puma settles Neratinib patent litigation with Sandoz; generic entry allowed Dec 2030","bullets":["Settlement and License Agreement with Sandoz fully resolves pending Hatch-Waxman litigation in New Jersey.","Sandoz receives a non-exclusive, royalty-free sublicense to key patents, including U.S. Patent No. 7,399,865 B2.","Sandoz may begin selling generic Neratinib on or about December 8, 2030, subject to adjustment.","Company and Wyeth also grant Sandoz a waiver of all regulatory exclusivities.","Settlement eliminates burden, expense, and uncertainties of further litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-029261","json":"https://secwatch.observer/filing/0001437749-22-029261.json","markdown":"https://secwatch.observer/filing/0001437749-22-029261.md","text":"https://secwatch.observer/filing/0001437749-22-029261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922029261/0001437749-22-029261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922029261/pbyi20221216_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:13:08.356818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}